


This article was downloaded by: [University of Tennessee At Martin]

On: 07 October 2014, At: 01:38

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn20>

Synthesis of Modified Nucleosides for Incorporation of Formyletheno and Carboxyetheno Adducts of Adenine Nucleosides into Oligonucleotides

Niangoran Koissi^a & Harri Lönnberg^a

^a Department of Chemistry, University of Turku, Turku, Finland

Published online: 10 Dec 2007.

To cite this article: Niangoran Koissi & Harri Lönnberg (2007) Synthesis of Modified Nucleosides for Incorporation of Formyletheno and Carboxyetheno Adducts of Adenine Nucleosides into Oligonucleotides, *Nucleosides, Nucleotides and Nucleic Acids*, 26:8-9, 1203-1206, DOI: [10.1080/15257770701527836](https://doi.org/10.1080/15257770701527836)

To link to this article: <http://dx.doi.org/10.1080/15257770701527836>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

SYNTHESIS OF MODIFIED NUCLEOSIDES FOR INCORPORATION OF FORMYLETHENO AND CARBOXYETHENO ADDUCTS OF ADENINE NUCLEOSIDES INTO OLIGONUCLEOTIDES

Niangoran Koissi and Harri Lönnberg □ *Department of Chemistry, University of Turku, Turku, Finland.*


□ *Three protected derivatives of 1,N⁶-ethenoadenine nucleosides, viz. 3-[5-O-(4,4'-dimethoxytrityl)-7-formyl- (1) and 7-(1,2-diacetyloxypropyl)-2'-deoxyadenosine (2), and 3-[5-O-(4,4'-dimethoxytrityl)-2-O-(tert-butyl dimethylsilyl)-7-(ethoxycarbonyl)adenosine (3), expected to allow introduction of formyletheno and carboxyethenoadenine adducts into oligonucleotides by the conventional phosphoramidite chemistry, have been synthesized.*

Keywords DNA base modifications; etheno adducts

INTRODUCTION

Lipid peroxidation (LPO) generates several aldehydes α,β -unsaturated aldehydes that generate a variety of DNA adducts, many of which are cyclic adducts bearing an extra ring. This additional ring prevents normal hydrogen bonds formation upon hybridization and, hence, interferes with the transfer of genetic information. While the cyclic adducts as such may be classified as mutagenic DNA lesions, those bearing an additional functional group that is able to interfere with the base-pairing and form cross-links, are of particular interest. A major hurdle for evaluation of the mutagenic potential or genotoxicity of this kind of adducted bases is their site-specific incorporation into oligonucleotides.^[1,2] We now report on synthesis of three appropriately protected 1,N⁶-ethenoadenine nucleosides (1–3) that are aimed at allowing introduction of formyletheno and carboxyetheno adducts of adenine into oligonucleotides by conventional phosphoramidite chemistry.

Address correspondence to Niangoran Koissi, Department of Chemistry, University of Turku, FIN 20014, Turku, Finland. E-mail: koissi@gmail.com




SCHEME 2 (a) HPE/H₂O₂/THF, 3 hours at 70°C; (b) Ac₂O/DMAP, pyr, 3 hours; (c) TBAF/THF, rt, 6 hours.

3:1 ratio. No depurination was observed. **4a** was desilylated with tetrabutylammonium fluoride (TBAF) in THF to obtain **5** and the 5'-hydroxy group was protected with 4,4-dimethoxytrityl chloride in pyridine. **4b** was, in turn, first tritylated to obtain **6** and the 3'-silyl protection was then selectively removed with triethylamine trihydrofluoride in THF.^[5] It is worth noting that **1**^[6] withstood overnight ammonolysis at room temperature. The imine formation of the formyl group was fully reversible.

In case protection of the formyl group turns out to be necessary, nucleoside **2** may be used for the same purpose: The 1,2-diol exposed upon ammonolysis readily can be oxidized to formyl group by sodium periodate under very mild conditions.^[7,8] The method described recently^[9] for preparation of (1-hydroxyhexyl)etheno adduct of 2'-deoxyadenosine was applied to the synthesis of nucleoside **2**. The key step of that approach is the reaction of adenine base with an appropriate formyl epoxide obtained from an α,β -unsaturated aldehyde by treatment with a mixture of trifluoroacetone, Oxone and EDTA in aqueous MeCN. Accordingly, 4-hydroxy-2-pentalenol (HPE) was oxidized with hydrogen peroxide to 2,3-epoxy-4-hydroxypentalenol and this was allowed to react with 5'-*O*-(4,4'-dimethoxytrityl)-2'-*O*-(*tert*-butyldimethylsilyl)-2'-deoxyadenosine (**7**) to obtain the (1,2-dihydroxypropyl)etheno adduct **8** (Scheme 2). The hydroxy functions were then acetylated with acetic anhydride in pyridine (**9**) and the 3'-silyl protection was removed with TBAF in THF to obtain **2**.^[10]

Nucleoside **3** allows introduction of a carboxyetheno adduct into oligonucleotides, providing that after the chain assembly the ethyl ester function is subjected to hydroxide ion catalyzed hydrolysis prior to ammonolysis. This nucleoside was prepared by reacting 5'-*O*-(4,4'-dimethoxytrityl)adenosine with methyl 2-bromo-3-oxopropanoate in dioxane to obtain **10** and protecting the 2'-hydroxy function of with a TBDMS group (Scheme 3). Silylation with 1 equiv. of TBDMSCl in THF expectedly gave a mixture of **3** and its 3'-silylated isomer, which was resolved by silica gel chromatography to obtain **3**.^[11] Reaction of 5'-*O*-(4,4'-dimethoxytrityl)adenosine with 2-bromo-3-oxopropanoate was also attempted, but it turned out to be less efficient. 2-Bromo-3-oxopropanoate



SCHEME 3 (a) DMTrCl, Py; (b) OHC-CHBr-COOEt,^[12] dioxane, 2 hours reflux, yield; (c) TBDMS-Cl/Im, 24 hours, chromatographic separation.

was synthesized from ethyl bromoacetate and ethyl formate as described previously.^[12]

REFERENCES

- Iwai, S. *Nucleosides, Nucleotides, and Nucleic Acids* **2006**, 25, 561.
- Barbin, A. *Mutat. Res.* **2000**, 462, 55.
- Okamoto, A.; Tainaka, K.; Saito, I. *Tetrahedron Lett.* **2002**, 43, 4581.
- a) Nair, V.; Offerman, R.J.; Turner, G.A. *J. Org. Chem.* **1984**, 49, 4021; b) Kronberg, L.; Sjöholm, R.; Karlsson, S. *Chem. Res. Toxicol.* **1992**, 5, 852; c) Mikkola, S.; Koissi, N.; Ketomäki, K.; Rauvala, S.; Neuvonen, K.; Lönnberg, H. *Eur. J. Org. Chem.* **2000**, 12, 2315.
- Pirrung, M.C.; Shuey, S.W.; Lever, D.C.; Fallon, L. *Bioorg. Med. Chem. Lett.* **1994**, 4, 1345.
- Compd. **1**: ¹H NMR (CDCl₃): δ 10.04 (CHO, s, 1H), 10.01 (H-5, s, 1H), 8.39 (H-2, s, 1H), 8.27 (H-8, s, 1H), 7.43–7.21 (DMTr, m, 9H), 6.81 (DMTr, dd, *J* = 4.0 and 9.5 Hz, 4H), 6.58 (H-1', d, *J* = 6.4, 1H), 4.77 (H-3', m, 1H), 4.23 (H-4', m, 1H), 3.78 (2 × OMe, s, 6H), 3.50 (H-5', dd, *J* = 4.7 and 10.2 Hz, 1H), 3.43 (H-5'', dd, *J* = 5.3 and 10.2 Hz, 1H), 2.88 (H-2', m, 1H), 2.65 (H-2'', m, 1H); HRMS (FAB) MH⁺: found 606.2352, calcd for C₃₄H₃₁N₅O₆ 606.2351.
- Trevisiol, E.; Renard, A.; Defrancq, E.; Lhomme, J. *Tetrahedron Lett.* **1997**, 38, 8687.
- Karino, N.; Ueno, Y.; Matsuda, A. *Nucleic Acids Res.* **2001**, 29, 2456.
- Carvalho, V.M.; Gasparutto, D.; Di Mascio, P.; Medeiros, M.H.G.; Cadet, J. *Bioorg. Med. Chem.* **2003**, 11, 2445.
- Compd. **2**: ¹H NMR (CDCl₃) 7.98 (H-5, s, 1H), 7.83 (H-2, s, 1H), 7.20–7.35 (DMTr, m, 9H), 6.85 (H-8, s, 1H), 6.69–6.77 (DMTr, m, 4H), 6.30 (H-1, dd, *J* = 8.0 and 5.6 Hz, 1H), 5.35 [-CH(OAc)-CH(OAc)Me, m, 1H], 4.27 [H-3 & -CH(OAc)-CH(OAc)Me, m, 2H], 3.99 (H-4, m, 1H), 3.71 (2 × OMe, s, 6H), 2.88 (H-5' & H-5'', m, 2H), 2.51 (H-2' & H-2'', m, 2H), 2.04 & 2.00 (2 × Ac, s, 2 × 3H), 1.18 (s, 3H, Me).
- Compd. **3**: δ 7.98 (H-5, s, 1H), 7.97 (H-2, s, 1H), 7.20–7.32 (DMTr, m, 9H), 6.95 (H-8, s, 1H), 6.77–6.79 (DMTr, m, 4H), 5.88 (H-1, d, *J* = 6.0 Hz, 1H), 4.38 (H-2, m, 1H), 3.77 (3 × OMe, s, 9H), 3.72–2.83 (H-3' & H-4', m, 2H), 3.42–3.46 (H-5, dd, *J* = 13.0 and < 2 Hz, 1H), 3.16–3.20 (H-5, dd, *J* = 13.0 and < 2 Hz, 1H), 0.72 (C-Me₃, s, 6H), 0.51 (C-Me₃, s, 3H), -0.08 (Si-Me, s, 6H).
- Gangjee, A.; Vidwands, A.; Elzein, E.; McGuire, J.J.; Queener, S.F.; Kisliuk, R.L. *J. Med. Chem.* **2001**, 44, 1993.